Fish oil supplements prevent mental illness; safe and effective alternative to antipsychotic drugs

Tuesday, February 02, 2010 by Mike Adams, the Health Ranger Editor of NaturalNews.com (See all articles...) Tags: fish oil, mental illness, health news

(NaturalNews) An important new study published in the Archives of General Psychiatry reveals that fish oil supplements beat mental illness. The study involved 81 people deemed to be at high risk for psychosis. The randomized, placebo-controlled study provided fish oil supplements to half the study subjects for just 12 weeks (the other half received placebo supplements). The results? While 11 people in the placebo group developed a psychotic disorder, only 2 in the fish oil group did.

Although the study was relatively small, it helps demonstrate the wide-ranging benefits of omega-3 fatty acids, which are thought to be the key nutritional factor in fish oils. We already know that omega-3 fatty acids / polyunsaturated fatty acids (PUFAs) help protect people against cardiovascular disease. We also know they can play a role in preventing diabetes and cancer. It's little surprise that they also protect against mental illness, given the importance of healthy fatty acids for the functioning of the nervous system.

As the BBC reports, Alison Cobb, from the mental health charity Mind, said in response to this study: "If young people can be treated successfully with fish oils, this is hugely preferable to treating them with antipsychotics, which come with a range of problems from weight gain to sexual dysfunction, whereas omega-3s are actually beneficial to their general state of health."

She's exactly right: Antipsychotic drugs actually cause diabetes. They promote blood sugar disorders and weight gain, among other problems. Some psychiatric drugs have also been linked to school shootings and violent outbursts (suicides, murders, etc.). They're also expensive and they pose an environmental hazard, since many of the chemicals used in those drugs pass right through the body and end up in waters downstream.

Fish oils have none of these negative side effects. In fact, they have positive effects throughout the body. That's why fish oils are such a remarkable solution to replace antipsychotic drugs: They're safer, cheaper and they work better!

You're supposed to keep taking drugs, says Big Pharma

The drug companies, of course, are terrified that people might learn this truth. They want to keep patients on expensive, patented antipsychotic drugs while discrediting "natural remedies" like fish oils or nutritional supplements. The entire war being waged against nutrition and supplements is, of course, nothing more than the pharmaceutical industry trying to protect its own turf by destroying the competition.

Because, let's face it: For (virtually) every popular pharmaceutical on the market, there's a nutritional supplement that works better (and that's also safer and more affordable). Antipsychotic drugs can be replaced with fish oils. Cholesterol drugs can be replaced with B vitamins. Anti-cancer drugs can be replaced with vitamin D and medicinal mushrooms. Diabetes drugs can be replaced with a healthy plant-based diet and targeted supplements. The list goes on and on...

Nutrition works so well that in this study, subjects experienced a protective effect from fish oils for an entire year even though they only took those fish oils for 12 weeks! Imagine how much better the outcome might have been if they continued on the fish oils for the entire year...

Get quality fish oils

Of course, when it comes to fish oils, don't settle for just any cheap fish oil supplement. Many of the cheaper store-bought brands are largely made of olive oil filler combined with a tiny amount of fish oil extract. Search out quality supplements or oils from companies like Moxxor, Nordic Naturals or Carlson Labs.

Make sure your supplements are free from heavy metals, pesticides and other residues. Make sure they are harvested in a truly sustainable way, and make sure you can trust the source to provide consistent quality.

Fish oils can provide astonishing health benefits. If the medical industry were truly honest about researching what works for patients rather than what makes money for drug companies, they would have openly prescribed fish oils long ago (and abandoned many of the antipsychotic drugs they still push).

But as you already know, the pharmaceutical industry isn't interested in what works for people unless it's something they can sell at monopoly prices. They don't want people to know about natural remedies, nutritional cures or healing foods. They would much rather see people stay ignorant about those things while pumping their minds full of advertisements and propaganda that ridiculously suggests the human brain is somehow deficient in Big Pharma's patented chemicals and that the only way you'll ever be truly healthy, happy or sane is to keep swallowing their pills for the rest of your life.

The real insanity in the world is not in the minds of mental patients; it's in the evil plans of the FDA, the WHO and the pharmaceutical cartel -- all of whom conspire to peddle dangerous medications when far safer, more natural and more effective alternatives are readily available.

Abstract of study from the Archives of General Psychiatry

Long-Chain Omega-3 Fatty Acids for Indicated Prevention of Psychotic Disorders
http://archpsyc.ama-assn.org/cgi/content/abs...

A Randomized, Placebo-Controlled Trial

G. Paul Amminger, MD; Miriam R. Schäfer, MD; Konstantinos Papageorgiou, MD; Claudia M. Klier, MD; Sue M. Cotton, PhD; Susan M. Harrigan, MSc; Andrew Mackinnon, PhD; Patrick D. McGorry, MD, PhD; Gregor E. Berger, MD
Arch Gen Psychiatry. 2010;67(2):146-154.

Context: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation.

Objective: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis.

Design: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007.

Setting: Psychosis detection unit of a large public hospital in Vienna, Austria.

Participants: Eighty-one individuals at ultra-high risk of psychotic disorder.

Interventions: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months.

Main Outcome Measures: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition.

Results: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). Omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups.

Conclusions: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states.

Trial Registration: clinicaltrials.gov Identifier: NCT00396643

Author Affiliations: Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria (Drs Amminger, Schäfer, Papageorgiou, and Klier); Orygen Research Centre, Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia (Drs Amminger, Cotton, Mackinnon, and McGorry and Ms Harrigan); and Department of Research and Education, The Schlössli Clinic, Oetwil am See, Switzerland (Dr Berger).

Other sources for this story include:
BBC:
http://news.bbc.co.uk/2/hi/health/8490937.st...

WSJ:
http://online.wsj.com/article/SB100014240527...